Scilex Holding Co (FRA:D8B0) ROC (Joel Greenblatt) %: -462.78% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:D8B0 Scilex Holding Co FRA:D8B0
39 GF Score
Price €6.40
GF Value €4.77
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Scilex Holding Co ROC (Joel Greenblatt) %?

Scilex Holding Co FRA:D8B0 -9.86% 39 ROC (Joel Greenblatt) % is -462.78% as of Mar. 2026. GuruFocus rates FRA:D8B0 with a GF Score™ of 39/100 and a GF Value™ of €4.77 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 981 Drug Manufacturers companies, Scilex Holding Co ranks worse than 96.74% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Scilex Holding Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -462.78%.

The historical rank and industry rank for Scilex Holding Co's ROC (Joel Greenblatt) % or its related term are showing as below:

FRA:D8B0' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4067.89   Med: -2124.83   Max: -685.91
Current: -2913.81

During the past 7 years, Scilex Holding Co's highest ROC (Joel Greenblatt) % was -685.91%. The lowest was -4067.89%. And the median was -2124.83%.

FRA:D8B0's ROC (Joel Greenblatt) % is ranked worse than
96.74% of 981 companies
in the Drug Manufacturers industry
Industry Median: 11.53 vs FRA:D8B0: -2913.81

Scilex Holding Co's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -13.60% per year.


Scilex Holding Co  (FRA:D8B0) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Scilex Holding Co ROC (Joel Greenblatt) % Related Terms


Scilex Holding Co ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Scilex Holding Co's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scilex Holding Co ROC (Joel Greenblatt) % Chart

Scilex Holding Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -2,186.90 -709.23 -4,027.54 -2,195.94 -2,287.73

Scilex Holding Co Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,858.84 -5,999.67 -40,765.10 -1,106.60 -462.78

FRA:D8B0 vs MIRA, NSRX, MDCX: ROC (Joel Greenblatt) % Comparison

For the Drug Manufacturers - General subindustry, Scilex Holding Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scilex Holding Co ROC (Joel Greenblatt) % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Scilex Holding Co's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Scilex Holding Co's ROC (Joel Greenblatt) % falls into.


FRA:D8B0
39GF Score
Scilex Holding Co FRA:D8B0
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scilex Holding Co ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(13.018 + 4.09 + 6.272) - (331.101 + 3.562 + 2.787)
=-314.07

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(9.21 + 3.92 + 3.659) - (357.271 + 2.763 + 0.21999999999997)
=-343.465

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Scilex Holding Co for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-111.304/( ( (24.268 + max(-314.07, 0)) + (23.834 + max(-343.465, 0)) )/ 2 )
=-111.304/( ( 24.268 + 23.834 )/ 2 )
=-111.304/24.051
=-462.78 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -462.78% mean?
Scilex Holding Co (FRA:D8B0) has a ROC (Joel Greenblatt) % of -462.78% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Scilex Holding Co and its competitors. According to the industry distribution chart, Scilex Holding Co ranks #949 out of 981 companies in the Drug Manufacturers industry, placing it in the top 96.7%.
Is Scilex Holding Co's ROC (Joel Greenblatt) % too high?
Scilex Holding Co's current ROC (Joel Greenblatt) % is -462.78%. Based on the distribution chart, Scilex Holding Co ranks #949 out of 981 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Scilex Holding Co has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Scilex Holding Co's ROC (Joel Greenblatt) % compare to MIRA and NSRX?
According to the Drug Manufacturers industry distribution chart, Scilex Holding Co ranks #949 out of 981 companies for ROC (Joel Greenblatt) %. This places Scilex Holding Co in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 11.53. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.53, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Scilex Holding Co and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scilex Holding Co's current ROC (Joel Greenblatt) % is -462.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scilex Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Scilex Holding Co (FRA:D8B0) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.77, compared to a current price of €6.40 — trading 34.2% above its estimated fair value. The current ROC (Joel Greenblatt) % is -462.78%. Scilex Holding Co's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Scilex Holding Co (FRA:D8B0), the current ROC (Joel Greenblatt) % is -462.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scilex Holding Co (FRA:D8B0) Overvalued in 2026?

Based on GuruFocus' analysis, Scilex Holding Co stock appears to be overvalued. The current stock price of €6.40 is trading 34.2% above its estimated GF Value™ of €4.77. GuruFocus considers Scilex Holding Co to be Significantly Overvalued.

Key valuation signals for FRA:D8B0:

  • ROC (Joel Greenblatt) %: -462.78%
  • GF Value™: €4.77 vs. price of €6.40 (34.2% above fair value)
  • GF Score™: 39/100 with 7 warning signs

No single metric tells the full story. See the FRA:D8B0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Scilex Holding Co Business Description

Other Exchanges SCLX:USA
Address 960 San Antonio Road, Palo Alto, CA, USA, 94303
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
39GF Score

Get the complete analysis for FRA:D8B0

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.40
Price
€4.77
GF Value